Track market-moving stories before they get noisy

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden lowered its stake in Medtronic PLC (NYSE:MDT – Free Report) by 3.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 253,329 shares of the medical technology company’s stock after selling 10,400 shares during the quarter. Andra AP fonden’s holdings in Medtronic were worth $21,951,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in MDT. Madison Asset Management LLC lifted its stake in Medtronic by 25.0% during the 1st quarter. Madison Asset Management LLC now owns 244,000 shares of the medical technology company’s stock worth $21,143,000 after acquiring an additional 48,784 shares in the last quarter. Convergence Investment Partners LLC grew its position in Medtronic by 82.8% in the 1st quarter. Convergence Investment Partners LLC now owns 46,789 shares of the medical technology company’s stock valued at $4,054,000 after acquiring an additional 21,196 shares in the last quarter. Commerzbank Aktiengesellschaft FI increased its stake in Medtronic by 9.0% during the first quarter. Commerzbank Aktiengesellschaft FI now owns 46,929 shares of the medical technology company’s stock worth $4,066,000 after purchasing an additional 3,879 shares during the period. Florida Financial Advisors LLC lifted its position in shares of Medtronic by 16.2% during the first quarter. Florida Financial Advisors LLC now owns 3,328 shares of the medical technology company’s stock worth $288,000 after purchasing an additional 465 shares in the last quarter. Finally, Leith Wheeler Investment Counsel Ltd. boosted its stake in shares of Medtronic by 1.4% in the first quarter. Leith Wheeler Investment Counsel Ltd. now owns 323,384 shares of the medical technology company’s stock valued at $28,021,000 after purchasing an additional 4,540 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Stock Up 0.1% Medtronic stock opened at $83.29 on Tuesday. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The stock has a market cap of $106.61 billion, a PE ratio of 22.33, a P/E/G ratio of 2.23 and a beta of 0.56. The stock’s fifty day moving average is $79.68 and its two-hundred day moving average is $87.84.

Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.81 billion during the quarter, compared to the consensus estimate of $9.62 billion. During the same period in the previous year, the business earned $1.62 EPS. Medtronic’s revenue for the quarter was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, sell-side analysts expect that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend The business also recently announced a quarterly dividend, which was paid on Friday, July 17th. Stockholders of record on Friday, June 26th were issued a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 3.5%. The ex-dividend date was Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio (DPR) is currently 77.21%.

Insider Activity In related news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This trade represents a 10.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.26% of the company’s stock.

Wall Street Analyst Weigh In Several brokerages recently weighed in on MDT. Barclays upped their target price on shares of Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 1st. Royal Bank Of Canada restated an “outperform” rating and issued a $118.00 price target on shares of Medtronic in a research note on Thursday, June 4th. Argus cut their price objective on Medtronic from $125.00 to $115.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. The Goldman Sachs Group reduced their price objective on Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a research note on Thursday, June 4th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $85.00 target price on shares of Medtronic in a report on Tuesday, June 16th. Seventeen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and a consensus target price of $98.21.

Read Our Latest Research Report on Medtronic

Medtronic Company Profile (Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

See Also Five stocks we like better than Medtronic The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Purchases 53,990 Shares of Thermo Fisher Scientific Inc. $TMO

NEXT HEADLINE »Andra AP fonden Has $24.38 Million Holdings in Incyte Corporation $INCY

It has been about a month since the last earnings report for Medtronic (MDT - Free Report) . Shares have added about 1.5% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Medtronic due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.

Medtronic's Q4 Earnings & Revenues Top EstimatesMedtronic plc posted fourth-quarter fiscal 2026 adjusted earnings of $1.55 per share, down 4.3% from the year-ago quarter but above the Zacks Consensus Estimate by 0.6%.

For the full-year fiscal 2026, adjusted earnings per share was $5.53, up 0.7% year over year. The figure missed the Zacks Consensus Estimate by 0.2%.

Revenue rose 9.9% year over year to $9.81 billion and beat the consensus by 1.5%. The upside came as procedure-driven demand stayed firm across key franchises. Cardiac Ablation Solutions revenue surged 78% globally, including 124% growth in the United States, while multiple portfolios delivered healthy gains.

Full-year worldwide revenues totaled $36.4 billion, up 8.4% year over year. The top line marginally surpassed the Zacks Consensus Estimate by 0.6%.

MDT’s Portfolio Mix Tilted Toward Cardiovascular

Cardiovascular generated $3.80 billion in the quarter, underscoring the importance of the company’s largest portfolio to overall momentum. Neuroscience contributed $2.75 billion, and Medical Surgical added $2.39 billion, reflecting steady demand across hospital-based therapy areas.

Diabetes produced $837 million of revenue and remained a meaningful growth lever alongside the broader portfolios. The mix shows Medtronic’s exposure to both large, recurring procedural categories and faster-moving product cycles in areas like diabetes management.

MDT’s Geographic Split Favored International Growth

U.S. revenue increased 7.1% year over year to $4.87 billion, supported by gains across major portfolios and continued procedure volume resilience.

International revenue advanced 12.8% to $4.94 billion. The overseas outperformance was broad-based and included a notable lift in Diabetes internationally, reinforcing how global scale can amplify Medtronic’s reported results when demand is healthy.

Medtronic’s Adjusted Margins Mixed in the Quarter

On an adjusted basis, Medtronic posted gross margin of 65.4% in fourth-quarter fiscal 2026, up 30 basis points year over year, reflecting a modest improvement in profitability at the product level.

However, operating leverage moved the other way. The adjusted operating margin fell to 25.5%, down 230 basis points from the prior-year quarter, as the company absorbed notable headwinds, including margin impacts tied to the MiniMed Blackstone payment and tariffs.

Medtronic’s Cash Generation Supports Returns and Investment

Operating cash flow totaled $7.33 billion in fiscal 2026, providing the financial flexibility to fund both portfolio investment and shareholder distributions. Free cash flow was $5.43 billion for the year, equal to 76% free cash flow conversion from adjusted net earnings.

Medtronic also returned $4.2 billion to shareholders in fiscal 2026 and ended the year with $9.2 billion in cash and investments.

Medtronic’s FY27 Guidance and Shareholder Returns

Looking ahead, the company guided for fiscal 2027 organic revenue growth of 6.75% to 7.25% and adjusted earnings of $5.90 to $6.00 per share. The outlook bakes in the benefit of a 53rd week, additional M&A and a full-year contribution from the Diabetes business, while also considering tariffs, interest and tax expense. The Zacks Consensus Estimate projects fiscal 2027 revenues of $38.39 billion, up 6.1% from fiscal 2026 levels, while earnings per share is expected to rise 9.7% to $6.08.

Medtronic also increased its quarterly dividend to $0.72 per share, implying an annual rate of $2.88 and marking its 49th consecutive year of dividend increases.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a upward trend in estimates revision.

VGM ScoresCurrently, Medtronic has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the second quintile for value investors.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Interestingly, Medtronic has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.